Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells

The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent

(2015) Chen Li et al.   CANCER BIOLOGY & THERAPY

Advances in the development of histone lysine demethylase inhibitors

(2015) Tamara Maes et al.   CURRENT OPINION IN PHARMACOLOGY

ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis

(2015) Li-sen Qin et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Progress in defining first-line and maintenance therapies

(2015) Joleen M. Hubbard et al.   Nature Reviews Clinical Oncology

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Towards improved drugs, combinations and patient selection

(2014) Hans-Joachim Schmoll et al.   Nature Reviews Clinical Oncology

Adjuvant chemotherapy for rectal cancer—an unresolved issue

(2014) Manisha Palta et al.   Nature Reviews Clinical Oncology

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

(2014) Katrina J. Falkenberg et al.   NATURE REVIEWS DRUG DISCOVERY

XAV939: From a Small Inhibitor to a Potent Drug Bioconjugate When Delivered by Gold Nanoparticles

(2013) Marwa M. Afifi et al.   BIOCONJUGATE CHEMISTRY

Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer

(2013) Giuseppe Tonini et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The short chain cell-permeable ceramide (C6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells

(2013) Li-sen Qin et al.   MOLECULAR BIOLOGY REPORTS

Colorectal cancer screening—optimizing current strategies and new directions

(2013) Ernst J. Kuipers et al.   Nature Reviews Clinical Oncology

Histone lysine demethylases as targets for anticancer therapy

(2013) Jonas W. Højfeldt et al.   NATURE REVIEWS DRUG DISCOVERY

Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis

(2011) Jennifer Jurkin et al.   CELL CYCLE

C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo

(2011) Q-y Zhu et al.   Cell Death & Disease

HDACs and HDAC inhibitors in colon cancer

(2010) John M. Mariadason   Epigenetics

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Oxaliplatin or Irinotecan As Adjuvant Therapy for Colon Cancer: The Results Are In

(2009) Michael J. O'Connell   JOURNAL OF CLINICAL ONCOLOGY

Abrogation of Mitogen-Activated Protein Kinase and Akt Signaling by Vandetanib Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis in Human Glioma Cells

(2009) E. P. Jane et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS